RxDoctor Payments DataLook up a doctor →

Wesley Chou, MD

Neurology · Bowling Green, KYNPI 1841294717

Payments from drug & device makers

$26,674in general payments, 2019–2025

Across 1,600 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$3K
  • UCB, Inc.$2K
  • AbbVie$2K
  • Amgen$1K
  • Neurocrine Biosciences, Inc.$1K
  • Novartis$1K
  • plus $16K from 54 others

What the payments were for

  • Travel & lodging$2661%
  • Food & beverage$26,02398%
  • Education$3851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen181$2,782
UCB, Inc.96$1,949
AbbVie(2 entities)144$1,698
Amgen(2 entities)74$1,380
Neurocrine Biosciences, Inc.57$1,272
Novartis82$1,153
Pfizer86$1,104
MDD US Operations, LLC41$1,023
EMD Serono, Inc.63$926
Lilly USA, LLC55$819
Lundbeck LLC38$675
AstraZeneca22$668
Neurelis, Inc.37$662
Jazz Pharmaceuticals Inc.29$656
Bristol Myers Squibb49$652
SK Life Science, Inc.34$629
Acadia Pharmaceuticals Inc36$608
Teva Pharmaceuticals USA, Inc.35$572
Supernus Pharmaceuticals, Inc.60$548
Catalyst Pharmaceuticals, Inc.23$474
Eisai Inc.28$461
Livanova USA, Inc.10$430
Sunovion Pharmaceuticals Inc.35$427
Biohaven Pharmaceuticals, Inc.25$411
Biohaven Pharmaceutical Holding Company Ltd.23$361
Genentech USA, Inc.20$340
CSL Behring19$337
Octapharma USA, Inc.5$313
Grifols USA, LLC17$303
Mallinckrodt Hospital Products Inc.13$280
Argenx US, Inc.13$260
Avanir Pharmaceuticals, Inc.18$256
Johnson & Johnson(2 entities)15$230
Alnylam Pharmaceuticals Inc.10$164
Upsher-smith Laboratories LLC9$140
Harmony Biosciences LLC6$128
Amneal Pharmaceuticals LLC8$126
Sumitomo Pharma America, Inc.10$112
Cycle Pharmaceuticals Inc4$107
Otsuka America Pharmaceutical, Inc.6$103
Arbor Pharmaceuticals, Inc.7$99
ANI Pharmaceuticals, Inc.5$85
Adamas Pharmaceuticals, Inc.5$84
Sanofi4$84
Mallinckrodt Enterprises LLC5$79
Kyowa Kirin, Inc.4$69
Axsome Therapeutics, Inc.3$64
TG Therapeutics, Inc.3$54
Xeris Pharmaceuticals, Inc.3$53
Akcea Therapeutics, Inc.1$43
Collegium Pharmaceutical, Inc.3$42
Ipsen Biopharmaceuticals, Inc2$40
Zogenix Inc.2$40
Portola Pharmaceuticals, LLC2$36
Abbott2$34
Monteris Medical Corporation1$30
Impel Pharmaceuticals Inc.1$20
Idorsia Pharmaceuticals US Inc1$20
Boston Scientific1$19
Takeda Pharmaceuticals U.S.A., Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,674 in reported general payments places this provider in the 75th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$78,689
Medicare patients
261
Services billed
1,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate13$112,061
UbrelvyUbrogepant100$91,704
QuliptaAtogepant67$91,471
Ajovy AutoinjectorFremanezumab-Vfrm51$49,511
Nurtec OdtRimegepant Sulfate38$39,761
Aimovig AutoinjectorErenumab-Aooe30$36,791
AptiomEslicarbazepine Acetate19$27,549
RytaryCarbidopa/Levodopa61$27,339
NuedextaDextromethorphan Hbr/Quinidine15$23,966
BrilintaTicagrelor34$23,550
FycompaPerampanel13$16,449
QuviviqDaridorexant Hcl22$10,418
SunosiSolriamfetol Hcl11$9,441
Ajovy SyringeFremanezumab-Vfrm12$8,646
Lacosamide38$8,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,698$183,175167 claims
BiogenVumerity$2,782$112,06113 claims
PfizerNurtec Odt$1,104$39,76138 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$126$35,10491 claims
Sunovion Pharmaceuticals Inc.Aptiom$427$27,54919 claims
Avanir Pharmaceuticals, Inc.Nuedexta$256$23,96615 claims
AstraZenecaBrilinta$668$23,55034 claims
Eisai Inc.Fycompa$461$16,44913 claims
Idorsia Pharmaceuticals US IncQuviviq$20$10,41822 claims
Axsome Therapeutics, Inc.Sunosi$64$9,44111 claims
Upsher-smith Laboratories LLCTopiramate$140$1,897122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 210 neurology providers in Kentucky.

Other neurology in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →